|
Index | - | P/E | - | EPS (ttm) | -3.14 | Insider Own | 7.40% | Shs Outstand | 27.40M | Perf Week | 41.79% |
Market Cap | 105.28M | Forward P/E | - | EPS next Y | -2.61 | Insider Trans | 0.00% | Shs Float | 25.44M | Perf Month | 66.81% |
Income | -85.50M | PEG | - | EPS next Q | -0.82 | Inst Own | 67.90% | Short Float / Ratio | 0.08% / 0.40 | Perf Quarter | 79.64% |
Sales | - | P/S | - | EPS this Y | -37.30% | Inst Trans | -6.06% | Short Interest | 0.02M | Perf Half Y | 36.90% |
Book/sh | 4.61 | P/B | 0.86 | EPS next Y | 16.30% | ROA | -45.60% | Target Price | 9.75 | Perf Year | -72.26% |
Cash/sh | 5.25 | P/C | 0.76 | EPS next 5Y | - | ROE | -55.00% | 52W Range | 1.95 - 14.86 | Perf YTD | 47.58% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -73.28% | Beta | - |
Dividend % | - | Quick Ratio | 8.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 103.59% | ATR | 0.39 |
Employees | 78 | Current Ratio | 8.40 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 72.75 | Volatility | 17.44% 11.99% |
Optionable | No | Debt/Eq | 0.08 | EPS Q/Q | -18.50% | Profit Margin | - | Rel Volume | 2.50 | Prev Close | 4.28 |
Shortable | Yes | LT Debt/Eq | 0.04 | Earnings | - | Payout | - | Avg Volume | 48.13K | Price | 3.97 |
Recom | 1.80 | SMA20 | 34.73% | SMA50 | 51.59% | SMA200 | 39.76% | Volume | 120,088 | Change | -7.24% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite